GSK gets US FDA approval for expanded use of RSV vaccine

March 13 (Reuters) – British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the ​approved age range for its ‌respiratory syncytial virus vaccine, Arexvy, to include adults aged 18 to 49 who are at increased risk of lower respiratory tract disease caused ‌by ​the virus.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by ​Devika Syamnath)